Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 10, 1996, Pages 1041-1048

  Kawasaki, T ^a   Kaku, S ^a   Sakai, Y ^a   Takenaka, T ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NOVO HEPARIN; PAMITEPLASE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; FIBRINOGENOLYSIS; HEART INFARCTION; HEPARINIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RECANALIZATION; THROMBOGENESIS;

EID: 0029848088     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb05897.x     Document Type: Article

References (33)

1. Badimon, L., Lassila, R., Badimon. J., Vallabhajosula, S., Chesebro, J. H., Fuster, V. (1988) Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 78 (suppl. II): 119
2. Bush, L. R., Mellot, M. J., Kanovsky, S. M., Holahan, M. A., Patrick, D. H. (1989) A model of femoral artery thrombolysis in dogs. Fibrinolysis 3: 107-114
3. Collen, D., Stump, D. L., Gold, H. K. (1988) Thrombolytic therapy. Ann. Rev. Med. 39: 405-423
4. Coller, B. S., Scudder, L. E., Beer, J., Gold, H. K., Folts, J. D., Cavagnaro, J., Jordan, R., Wagner, C., Iuliucci, J., Knight, D., Ghrayeb, J., Smith, C., Weisman, H. F., Berger, H. (1991) Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. New York Acad. Sci. 614: 193-213
5. Cook, J. J., Sitko, G. R., Bednar, B., Condra, C., Mellot, M. J., Feng, D.-M., Nutt, R. F., Shafer, J. A., Gould, R. J., Connolly, T. M. (1995) An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91: 2961-2971
6. Gold, H. K., Leinbach, R. C., Garabedian, H. D., Yasuda, T., Johns, A., Grossbard, E. B., Palacios, I., Collen, D. (1986) Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73: 347-352
7. Grunewald, M., Ellbruck, D., Mohren, M., Schirmer, G., Osterhues, H., Ziesche, S., Gluloglu, A., Bock, R., Seifried, E. (1995) Single vs double bolus thrombolysis with recombinant plasminogen activator BM06.022 in patients with acute myocardial infarction-pharmacokinetics and hemostatic changes. Thromb. Haemost. 73: 1328
8. Guesdon, J. L., Ternynck, T., Avrameas, S. (1979) The use of avidinbiotin interaction in immunoenzymatic techniques. J. Histochem. Cytochem. 27: 1131-1139
9. Hans, J., Hua, R. L., Zaomin, W., Herman, N., Collen, D. (1991) Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. Blood 77: 1020-1024
10. Hara, T., Yokoyama, A., Ishihara, H., Yokoyama, Y., Nagahara, T., Iwamoto, M. (1995) DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemost. 71: 314-319
11. Hogg, P. J., Jackson, C. G. (1989) Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. USA 86: 3619-3623
12. Johns, J. A., Gold, H. K., Leinbach, R. C., Yasuda, T., Gimple, W., Werner, W., Finkelstein, D., Newell, J. B., Ziskind, A. A., Collen, D. (1988) Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction: a randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation 78: 546-556
13. Kaku S., Kawasaki, T., Sakai, Y., Taniuchi, Y., Yano, S., Suzuki, K., Terazaki, C., Kawamura, K., Masuho, Y., Satoh, N., Takenaka, T., Yanagi, K., Ohshima, N. (1995) Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. Eur. J. Pharmacol. 279: 115-121
14. Katoh, M., Suzuki, Y., Miyamoto, I., Watanabe, T., Mori, K., Arakawa, H., Gushima, H. (1991) Biochemical and pharmacokinetic properties of YM866, a novel fibrinolytic agent. Thromb. Haemost. 65: 1193
15. Kawasaki, T., Katoh, M., Kaku, S., Gushima, H., Takenaka, T., Yui, Y., Kawai, C. (1993) Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J. Pharmacol. 63: 9-16
16. Kawasaki, T., Kaku, S., Sakai, Y., Takenaka, T. (1994a) Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a rabbit model of jugular vein thrombosis. Drug Dev. Res. 33: 33-38
17. Kawasaki, T., Katoh, M., Takenaka, T., Yanagi, K., Ohshima, N. (1994b) Thrombolytic activity of YM866, a novel modified tissuetype plasminogen activator, in a photochemically induced plateletrich thrombosis model. J. Cardiovasc. Pharmacol. 23: 884-889
18. Kawauchi, Y., Morinaga, T., Yokota, M., Kinoshita, A., Kawamura, K., Suzuki, Y., Takayama, M., Furuichi, K., Gushima, H. (1991) Gene construction and large scale production of a novel fibrinolytic agent (YM866) in CHO cells. Thromb. Haemost. 65: 1193
19. Khan, M. I., Hackett, D. R., Andreotti, F., Davies, G. J., Regan, T., Haider, A. W., McFadden, E., Halson, P., Maseri, A. (1990) Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 65: 1051-1056
20. Martin, U., Sponer, G., Strein, K. (1992) Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM06.022 compared with alteplase, anistreplase, strepiokinase and urokinase in a canine model of coronary artery thrombosis. J. Am. Coll. Cardiol. 19: 433-440
21. Mellot, M. J., Connolly, T. M., York, S. J., Bush, L. R. (1990) Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following tPA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb. Haemost. 64: 526-534
22. Nicholson, N. S., Panzer-Knodle, S. G., Salyers, A. K., Taite, B. B., Szalony, J. A., Haas, N. F., King, L. W., Zablocki, J. A., Keller, B. T., Broschat, K., Engleman, V. W., Herin, M., Jacqmin, P., Feigen, L. P. (1995) SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 91: 403-410
23. Ratnoff, O. D., Menzie, C. (1951) A new method for the determination of fibrinogen in small samples of plasma. J. Lab. Clin. Med. 37: 316-320
24. Rentrop, K. P. (1985) Thrombolytic therapy in patients with acute myocardial infarction. Circulation 71: 627-631
25. Saito, M., Suzuki, S., Yui, Y., Kawai, C. (1994) A modified tissue-type plasminogen activator (tPA), E6010, gradually increases coronary blood flow after thrombolysis compared with native tPA, urokinase, and balloon catheter occlusion-reperfusion. Jpn J. Pharmacol. 66: 17-23
26. Simoons, M. L., Arnold, A. E. R., Betriu, A., De Bono, D. P., Col, J., Dougherty, F. C., von Essen, R., Lambertz, H., Lubsen, J., Meier, B., Michel, P. L., Raynaud, P., Rutsch, W., Sanz, G. A., Schmidt, W., Serruys, P. W., Thery, C., Uebis, R., Vahanian, A., Van de Werf, F., Willems, G. M., Wood, D., Verstraete, M. (1988) Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1: 197-202
27. Suzuki, S., Saito, M., Suzuki, N., Kato, H., Nagaoka, N., Yoshitake, S., Mizuo, H., Yuzuriha, T., Yui, Y., Kawai, C. (1991) Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J. Cardiovasc. Pharmacol. 17: 738-746
28. Tebbe, U., Transwell, P., Seifried, E., Feuerer, W., Scholz, K. H., Herrmann, K. S. (1989) Single bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 64: 448-453
29. The International Study Group (1990) In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336: 71-75
30. Tiefenbrunn, A. J., Robison, A. K., Kurnik, P. B., Ludbrook, P. A., Sobel, B. E. (1985) Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 71: 110-116
31. Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., Hirsh, J. (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86: 385-391
32. Wohl, R. C., Sinio, L., Summaria, L., Robbins, K. C. (1983) Comparative activation kinetics of mammalian plasminogens. Biochim. Biophys. Acta 745: 20-31
33. Zahger, D., Fishbein, M, C., Garfinkel, L. I., Shah, P. K., Forrester, J. S., Regnstrom, J., Yano, J., Cercek, B. (1995) VCL, an antagonist of the platelet GPIb receptor, markedly inhibits platelet adhesion and intimai thickening after balloon injury in the rat. Circulation 92: 1269-1273